# Folinic Acid Improves Healing of Diabetic Foot Ulcers

**Authors:** Glenn D. Hoke, Annjanette Stone, Michael A. Bauer, Weleetka C. Carter, Megan R. Newsom, Joseph V. Boykin

PMC · DOI: 10.1111/wrr.70141 · Wound Repair and Regeneration · 2026-03-07

## TL;DR

Folinic acid treatment significantly improves healing of diabetic foot ulcers by reducing inflammation and promoting tissue repair.

## Contribution

A novel folinic acid wound treatment was shown to significantly enhance diabetic foot ulcer healing through anti-inflammatory mechanisms.

## Key findings

- FAWT led to an 88% reduction in DFU area compared to 40% in the control group after 12 weeks.
- FAWT decreased HMGB1 and IL-1B protein levels, indicating reduced inflammation.
- FAWT induced methylation changes in microRNAs that may inhibit proinflammatory pathways.

## Abstract

A novel folinic acid (FA) wound treatment (FAWT) significantly (p < 0.05) improved healing (re‐epithelialization) of chronic diabetic foot ulcers (DFUs). In a double‐blind RCT, 10 (n = 10) chronic DFU subjects received daily topical treatment in either the Control group [(n = 5); PluroGel] or the FAWT group [(n = 5); PluroGel with FA 2.5%]. After 12 weeks, FAWT subjects experienced significantly (p < 0.05) greater %‐DFU area reduction (88% [SD: 16]) vs. Control (40% [SD: 39]), respectively. Proteomic analysis of keratinocytes (KCs) pre‐ and post‐FAWT, using Reverse Phase Proteomic Array (RPPA), documented significantly decreased levels of HMGB1 (High Mobility Group Box1) protein and activated IL‐1B protein at 12 weeks after FAWT as compared to Control. RPPA also documented significantly decreased activating phosphorylation of SAP/JNK3 (T183/Y185) and p38 MAPK (T180/Y182) levels after FAWT as compared to Control. These findings suggested decreased activation and possible reduction of NFKB/p65 and p38 MAPK following FAWT that could decrease proinflammatory gene expression. Genomic DNA‐methylation analysis of KCs identified significantly decreased FAWT‐induced methylation at gene expression regulatory sites for multiple microRNAs (MiRNA) associated with regulating proinflammatory responses. FAWT‐induced decreased methylation levels in MiRNAs suggested increased expression and their potential to inhibit protein translation. These MiRNAs are predicted to target multiple mitogen‐activated protein kinase (MAPK) pathways. These MAPK pathways mediate signalling from proinflammatory cell surface receptors (such as RAGE, TLRs and IL1R), altering gene expression. FAWT‐induced inhibition of MAPK‐signalling may lessen NFKB/p65 and p38 MAPK induction of proinflammatory gene expression, reflected in the significantly decreased protein levels of HMGB1 and IL‐1B. The data suggest FAWT‐induced coordinated expression of multiple anti‐inflammatory MiRNAs associated with impaired MAPK‐signalling that resulted in decreased expression of HMGB1 and IL1B and this process may facilitate DFUs' transition from an inflammatory state to wound repair, enabling KCs to regulate their proliferative phase, migration and the promotion of DFU re‐epithelialization.

## Linked entities

- **Genes:** HMGB1 (high mobility group box 1) [NCBI Gene 3146], IL1B (interleukin 1 beta) [NCBI Gene 3553], P38mapk (p38 map kinase) [NCBI Gene 692545]
- **Proteins:** HMGB1 (high mobility group box 1), IL1B (interleukin 1 beta), P38mapk (p38 map kinase)
- **Chemicals:** Folinic Acid (PubChem CID 135402009)

## Full-text entities

- **Genes:** IL10 (interleukin 10) [NCBI Gene 3586] {aka CSIF, GVHDS, IL-10, IL10A, TGIF}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, DAPK1 (death associated protein kinase 1) [NCBI Gene 1612] {aka DAPK, ROCO3}, MOK (MOK protein kinase) [NCBI Gene 5891] {aka RAGE, RAGE-1, RAGE1, STK30}, SP1 (Sp1 transcription factor) [NCBI Gene 6667], LDHA (lactate dehydrogenase A) [NCBI Gene 3939] {aka GSD11, HEL-S-133P, LDHM, PIG19}, MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}, IARS1 (isoleucyl-tRNA synthetase 1) [NCBI Gene 3376] {aka GRIDHH, IARS, ILERS, ILRS, IRS, PRO0785}, SP3 (Sp3 transcription factor) [NCBI Gene 6670] {aka SPR2}, TLR4 (toll like receptor 4) [NCBI Gene 7099] {aka ARMD10, CD284, TLR-4, TOLL}, MIR7-2 (microRNA 7-2) [NCBI Gene 407044] {aka MIRN7-2, hsa-mir-7-2, mir-7-2}, SH2D1A (SH2 domain containing 1A) [NCBI Gene 4068] {aka DSHP, EBVS, IMD5, LYP, MTCP1, SAP}, APCS (amyloid P component, serum) [NCBI Gene 325] {aka HEL-S-92n, PTX2, SAP}, MIR933 (microRNA 933) [NCBI Gene 100126350] {aka MIRN933, hsa-mir-933, mir-933}, MAPK10 (mitogen-activated protein kinase 10) [NCBI Gene 5602] {aka JNK3, JNK3A, PRKM10, SAPK1b, p493F12, p54bSAPK}, PIK3R1 (phosphoinositide-3-kinase regulatory subunit 1) [NCBI Gene 5295] {aka AGM7, GRB1, IMD36, p85, p85-ALPHA, p85alpha}, TLR2 (toll like receptor 2) [NCBI Gene 7097] {aka CD282, TIL4}, MAPK1 (mitogen-activated protein kinase 1) [NCBI Gene 5594] {aka ERK, ERK-2, ERK2, ERT1, MAPK2, NS13}, STAT3 (signal transducer and activator of transcription 3) [NCBI Gene 6774] {aka ADMIO, ADMIO1, APRF, HIES}, MAPK8 (mitogen-activated protein kinase 8) [NCBI Gene 5599] {aka JNK, JNK-46, JNK1, JNK1A2, JNK21B1/2, PRKM8}, CREB1 (cAMP responsive element binding protein 1) [NCBI Gene 1385] {aka CREB, CREB-1}, RPS6KA5 (ribosomal protein S6 kinase A5) [NCBI Gene 9252] {aka MSK1, MSPK1, RLPK}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, COX2 (cytochrome c oxidase subunit II) [NCBI Gene 4513] {aka COII, MTCO2}, BAK1 (BCL2 antagonist/killer 1) [NCBI Gene 578] {aka BAK, BAK-LIKE, BCL2L7, CDN1}, ELK1 (ETS transcription factor ELK1) [NCBI Gene 2002], AGER (advanced glycosylation end-product specific receptor) [NCBI Gene 177] {aka RAGE, SCARJ1, sRAGE}, MAP2K4 (mitogen-activated protein kinase kinase 4) [NCBI Gene 6416] {aka JNKK, JNKK1, MAPKK4, MEK4, MKK4, PRKMK4}, HMGB1 (high mobility group box 1) [NCBI Gene 3146] {aka HMG-1, HMG1, HMG3, SBP-1}, MAP3K5 (mitogen-activated protein kinase kinase kinase 5) [NCBI Gene 4217] {aka ASK1, MAPKKK5, MEKK5}, MYD88 (MYD88 innate immune signal transduction adaptor) [NCBI Gene 4615] {aka IMD68, MYD88D, WM1}, RPS6KA1 (ribosomal protein S6 kinase A1) [NCBI Gene 6195] {aka HU-1, MAPKAPK1, MAPKAPK1A, RSK, RSK1, p90Rsk}, TRAF6 (TNF receptor associated factor 6) [NCBI Gene 7189] {aka MGC:3310, RNF85}, SLTM (SAFB like transcription modulator) [NCBI Gene 79811] {aka Met}, CASP9 (caspase 9) [NCBI Gene 842] {aka APAF-3, APAF3, ICE-LAP6, MCH6, PPP1R56}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, RELA (RELA proto-oncogene, NF-kB subunit) [NCBI Gene 5970] {aka AIF3BL3, CMCU, NFKB3, p65}, ATF1 (activating transcription factor 1) [NCBI Gene 466] {aka EWS-ATF1, FUS/ATF-1, TREB36}, EGFR (epidermal growth factor receptor) [NCBI Gene 1956] {aka ERBB, ERBB1, ERRP, HER1, NISBD2, NNCIS}, IL1R1 (interleukin 1 receptor type 1) [NCBI Gene 3554] {aka CD121A, CRMO3, D2S1473, IL-1R-alpha, IL-1RT1, IL1R}, EGR2 (early growth response 2) [NCBI Gene 1959] {aka AT591, CMT1D, CMT4E, KROX20}, MAPK14 (mitogen-activated protein kinase 14) [NCBI Gene 1432] {aka CSBP, CSBP1, CSBP2, CSPB1, EXIP, Mxi2}, MIR4259 (microRNA 4259) [NCBI Gene 100422852], IKBKB (inhibitor of nuclear factor kappa B kinase subunit beta) [NCBI Gene 3551] {aka IKK-2, IKK-beta, IKK2, IKKB, IMD15, IMD15A}, MAP3K7 (mitogen-activated protein kinase kinase kinase 7) [NCBI Gene 6885] {aka CSCF, FMD2, MEKK7, TAK1, TGF1a}, TNFRSF1A (TNF receptor superfamily member 1A) [NCBI Gene 7132] {aka CD120a, FPF, TBP1, TNF-R, TNF-R-I, TNF-R55}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, MAPK9 (mitogen-activated protein kinase 9) [NCBI Gene 5601] {aka JNK-55, JNK2, JNK2A, JNK2ALPHA, JNK2B, JNK2BETA}
- **Diseases:** Mitochondrial dysfunction (MESH:D028361), alcohol (MESH:D000437), diabetic complications (MESH:D048909), pain (MESH:D010146), Hyperglycemia (MESH:D006943), abscess (MESH:D000038), inflammation (MESH:D007249), STI (MESH:D018461), DFU (MESH:D017719), proinflammatory diseases (MESH:D004194), chronic vascular insufficiency (MESH:D051436), DM (MESH:D009223), TBI (MESH:D000070642), diabetes (MESH:D003920), proinflammatory TFs (MESH:D005171), infected (MESH:D007239), diabetic neuropathy (MESH:D003929), substance abuse (MESH:D019966), osteomyelitis (MESH:D010019), depression (MESH:D003866), neuropathic (MESH:D009437), cellulitis (MESH:D002481), T2DM (MESH:D003924), chronic (MESH:D002908), neuropathy (MESH:D009422), gangrene (MESH:D005734)
- **Chemicals:** pyruvate (MESH:D019289), Advanced Glycation End (-), OCT (MESH:C051883), Ser (MESH:D012694), Lactate (MESH:D019344), FA (MESH:D002955), Humira (MESH:D000068879), steroid (MESH:D013256), prednisone (MESH:D011241), AGE (MESH:D017127), water (MESH:D014867), ATP (MESH:D000255), folate (MESH:D005492), glucose (MESH:D005947), DAMPs (MESH:C116255), SDS (MESH:D012967), Bisulfite (MESH:C042345)
- **Species:** Homo sapiens (human, species) [taxon 9606], Kunsagivirus C (no rank) [taxon 2169966]
- **Mutations:** (H) by 16, A1C

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12967698/full.md

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12967698/full.md

## References

43 references — full list in the complete paper: https://tomesphere.com/paper/PMC12967698/full.md

---
Source: https://tomesphere.com/paper/PMC12967698